Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced an exclusive global license agreement with Valneva SE (Nasdaq: ...

New data suggest a microbiota-based therapy can reduce C diff recurrence in patients where donor microbiota and patient microbiota successfully converge. A new report suggests microbiota-based ...

Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...

The role of food in Clostridioides difficile transmission chains still needs to be clarified, according to a study. Clostridioides difficile infection (CDI) is a notable cause of infectious diarrhea ...

SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has completed ...

Fidaxomicin, now commonly used to treat Clostridioides difficile infection, selectively targets the bacterium while sparing crucial gut commensals that protect against colonization. However, knowledge ...

Clostridioides difficile infection is the leading cause of healthcare-associated infections, resulting in high rates of mortality, with upto 35% of patients experiencing recurrent infections.

Gastrointestinal tumors remain a global health challenge, with high incidence and mortality. Among them, colorectal cancer (CRC) carries the heaviest burden and serves as a key model for how the gut ...

After the first year of interventions at Emory Saint Joseph's Hospital, there was a 63% decrease in hospital-onset C. diff cases as compared to the two years prior. Through a series of interventions ...

Mice fed a high-fat, high-protein diet were more likely to develop and die from antibiotic-driven Clostridioides difficile infections than mice fed a standard diet. In the same study, a ...